{"entity":{"type":"insider","cik":"0001385118","url":"/insider/0001385118","json_url":"/insider/0001385118.json","name":"Shaaltiel Yoseph","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":12,"first":"2007-12-12","last":"2012-05-04","span_basis":"filed_date"},"name_variants":[{"name":"Shaaltiel Yoseph","source":"filing","n_filings":12,"first_seen":"2007-12-12","last_seen":"2012-05-04"}],"transactions":[{"id":3473097,"accession":"0001144204-12-026355","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-12-026355","line_url":"/filing/0001144204-12-026355#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300000.0,"shares_display":"300,000","price_per_share":7.13,"price_display":"7.13","price_state":"stated","total_value":2139000.0,"total_display":"2,139,000.00","total_whole":"2,139,000","shares_owned_after":463754.0,"shares_owned_after_display":"463,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-05-02","filed_date":"2012-05-04","scope":"insider"},{"id":7630276,"accession":"0001209191-10-041740","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-10-041740","line_url":"/filing/0001209191-10-041740#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4619.0,"shares_display":"4,619","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":32333.0,"total_display":"32,333.00","total_whole":"32,333","shares_owned_after":763754.0,"shares_owned_after_display":"763,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-08-06","filed_date":"2010-08-09","scope":"insider"},{"id":7630274,"accession":"0001209191-10-041740","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-041740","line_url":"/filing/0001209191-10-041740#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48408.0,"shares_display":"48,408","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":338856.0,"total_display":"338,856.00","total_whole":"338,856","shares_owned_after":768373.0,"shares_owned_after_display":"768,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-08-05","filed_date":"2010-08-09","scope":"insider"},{"id":7531262,"accession":"0001209191-10-035483","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-035483","line_url":"/filing/0001209191-10-035483#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52973.0,"shares_display":"52,973","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":370811.0,"total_display":"370,811.00","total_whole":"370,811","shares_owned_after":816781.0,"shares_owned_after_display":"816,781","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-06-21","filed_date":"2010-06-23","scope":"insider"},{"id":7330807,"accession":"0001209191-10-024792","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-024792","line_url":"/filing/0001209191-10-024792#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12691.0,"shares_display":"12,691","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":88837.0,"total_display":"88,837.00","total_whole":"88,837","shares_owned_after":869754.0,"shares_owned_after_display":"869,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-04-29","filed_date":"2010-05-03","scope":"insider"},{"id":7457153,"accession":"0001209191-10-022637","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-022637","line_url":"/filing/0001209191-10-022637#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1309.0,"shares_display":"1,309","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":9163.0,"total_display":"9,163.00","total_whole":"9,163","shares_owned_after":882445.0,"shares_owned_after_display":"882,445","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-04-14","filed_date":"2010-04-16","scope":"insider"},{"id":7329425,"accession":"0001209191-10-018791","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-10-018791","line_url":"/filing/0001209191-10-018791#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":350000.0,"total_display":"350,000.00","total_whole":"350,000","shares_owned_after":883754.0,"shares_owned_after_display":"883,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-25","filed_date":"2010-03-25","scope":"insider"},{"id":7329423,"accession":"0001209191-10-018791","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-10-018791","line_url":"/filing/0001209191-10-018791#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":202700.0,"shares_display":"202,700","price_per_share":7.08,"price_display":"7.08","price_state":"stated","total_value":1435116.0,"total_display":"1,435,116.00","total_whole":"1,435,116","shares_owned_after":933754.0,"shares_owned_after_display":"933,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-24","filed_date":"2010-03-25","scope":"insider"},{"id":7329420,"accession":"0001209191-10-018791","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-10-018791","line_url":"/filing/0001209191-10-018791#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":127300.0,"shares_display":"127,300","price_per_share":7.02,"price_display":"7.02","price_state":"stated","total_value":893646.0,"total_display":"893,646.00","total_whole":"893,646","shares_owned_after":1136454.0,"shares_owned_after_display":"1,136,454","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-23","filed_date":"2010-03-25","scope":"insider"},{"id":5646864,"accession":"0001209191-09-049180","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-049180","line_url":"/filing/0001209191-09-049180#line-3","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":43120.0,"shares_display":"43,120","price_per_share":9.43,"price_display":"9.43","price_state":"stated","total_value":406621.6,"total_display":"406,621.60","total_whole":"406,622","shares_owned_after":1263754.0,"shares_owned_after_display":"1,263,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-10-19","filed_date":"2009-10-19","scope":"insider"},{"id":5646863,"accession":"0001209191-09-049180","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-049180","line_url":"/filing/0001209191-09-049180#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25680.0,"shares_display":"25,680","price_per_share":9.39,"price_display":"9.39","price_state":"stated","total_value":241135.2,"total_display":"241,135.20","total_whole":"241,135","shares_owned_after":1306874.0,"shares_owned_after_display":"1,306,874","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-10-16","filed_date":"2009-10-19","scope":"insider"},{"id":5646862,"accession":"0001209191-09-049180","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-049180","line_url":"/filing/0001209191-09-049180#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31200.0,"shares_display":"31,200","price_per_share":9.39,"price_display":"9.39","price_state":"stated","total_value":292968.0,"total_display":"292,968.00","total_whole":"292,968","shares_owned_after":1332554.0,"shares_owned_after_display":"1,332,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-10-15","filed_date":"2009-10-19","scope":"insider"},{"id":5711215,"accession":"0001209191-09-036036","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-036036","line_url":"/filing/0001209191-09-036036","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":5.094,"price_display":"5.09","price_state":"stated","total_value":509400.0,"total_display":"509,400.00","total_whole":"509,400","shares_owned_after":1383754.0,"shares_owned_after_display":"1,383,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-07-06","filed_date":"2009-07-08","scope":"insider","n_lines":2},{"id":5702752,"accession":"0001209191-09-027918","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-027918","line_url":"/filing/0001209191-09-027918#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":3.85,"price_display":"3.85","price_state":"stated","total_value":38500.0,"total_display":"38,500.00","total_whole":"38,500","shares_owned_after":1463754.0,"shares_owned_after_display":"1,463,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-05-14","filed_date":"2009-05-20","scope":"insider"},{"id":5702751,"accession":"0001209191-09-027918","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-027918","line_url":"/filing/0001209191-09-027918#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20000.0,"shares_display":"20,000","price_per_share":3.51,"price_display":"3.51","price_state":"stated","total_value":70200.0,"total_display":"70,200.00","total_whole":"70,200","shares_owned_after":1473754.0,"shares_owned_after_display":"1,473,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-05-13","filed_date":"2009-05-20","scope":"insider"},{"id":5965310,"accession":"0001209191-09-016289","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-016289","line_url":"/filing/0001209191-09-016289#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8300.0,"shares_display":"8,300","price_per_share":2.18,"price_display":"2.18","price_state":"stated","total_value":18094.0,"total_display":"18,094.00","total_whole":"18,094","shares_owned_after":1493754.0,"shares_owned_after_display":"1,493,754","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-03-13","filed_date":"2009-03-13","scope":"insider"},{"id":6936852,"accession":"0001385118-07-000002","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001385118-07-000002","line_url":"/filing/0001385118-07-000002#line-4","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4800.0,"shares_display":"4,800","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":16320.0,"total_display":"16,320.00","total_whole":"16,320","shares_owned_after":2974107.0,"shares_owned_after_display":"2,974,107","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-19","filed_date":"2007-12-26","scope":"insider"},{"id":6936849,"accession":"0001385118-07-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001385118-07-000002","line_url":"/filing/0001385118-07-000002","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5100.0,"shares_display":"5,100","price_per_share":3.399019607843137,"price_display":"3.40","price_state":"stated","total_value":17335.0,"total_display":"17,335.00","total_whole":"17,335","shares_owned_after":2969307.0,"shares_owned_after_display":"2,969,307","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-18","filed_date":"2007-12-26","scope":"insider","n_lines":2},{"id":6936838,"accession":"0001385118-07-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001385118-07-000002","line_url":"/filing/0001385118-07-000002#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":3.35,"price_display":"3.35","price_state":"stated","total_value":16750.0,"total_display":"16,750.00","total_whole":"16,750","shares_owned_after":2964207.0,"shares_owned_after_display":"2,964,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-17","filed_date":"2007-12-26","scope":"insider"},{"id":7796354,"accession":"0001385118-07-000001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001385118-07-000001","line_url":"/filing/0001385118-07-000001","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":"0001385118","owner_name":"Shaaltiel Yoseph","owner_display_name":"Shaaltiel Yoseph","owner_url":"/insider/0001385118","role":"Director, Officer (Executive VP, R&D)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, R&D","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15100.0,"shares_display":"15,100","price_per_share":3.1382781456953643,"price_display":"3.14","price_state":"stated","total_value":47388.0,"total_display":"47,388.00","total_whole":"47,388","shares_owned_after":2955907.0,"shares_owned_after_display":"2,955,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-05","filed_date":"2007-12-12","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":24,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":7,"open_market":true},{"code":"S","label":"Open-market sale","n":17,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":24},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001006281","name":"Protalix BioTherapeutics, Inc.","url":"/issuer/0001006281","role":"Director, Officer (Executive VP, R&D)","n_filings":12,"first_seen":"2007-12-12","last_seen":"2012-05-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001385118","retrieved_at":"2026-08-26T07:40:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}